Last edition
News about "monotherapy"
Lupin and Zydus Partner to Co-Market Semaglutide Injection in India
Lupin has secured semi-exclusive rights to co-market Zydus’ Semaglutide injection in India under the brands Semanext and Livarise, while Zydus will continue marketing it under the brand names SEMAGLYNTM, MASHEMATM and ALTERMETM.
Monotherapy | 18/03/2026 | By News Bureau | 211
IDEAYA Biosciences Enrols First Patient in Phase I Trial of IDE034 Bispecific TOP1 ADC
Precision oncology firm IDEAYA begins Phase I evaluation of IDE034, a PTK7/B7H3 bispecific TOP1 ADC, advancing its ADC and DNA damage response combination strategy in solid tumours.
Monotherapy | 02/03/2026 | By News Bureau | 124
CStone Pharmaceuticals Secures UK MHRA Approval for Sugemalimab in Stage III NSCLC
The UK Medicines and Healthcare products Regulatory Agency grants a new indication for sugemalimab monotherapy in unresectable Stage III NSCLC, expanding its European footprint and global commercial reach.
Monotherapy | 23/02/2026 | By News Bureau | 217
Pin Therapeutics Administers First Dose of PIN-5018 in Adenoid Cystic Carcinoma Patient
Pin Therapeutics, a clinical-stage biotechnology company focused on targeted protein degradation, has begun dosing in a Phase 1 clinical trial evaluating its CK1α-selective degrader, PIN-5018. The first patient enrolled in the study has adenoid cystic carcinoma (ACC), a rare malignancy with limited treatment options.
Monotherapy | 24/11/2025 | By Dineshwori | 303
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy